David M. Margolis

30.3k total citations · 4 hit papers
304 papers, 16.0k citations indexed

About

David M. Margolis is a scholar working on Virology, Infectious Diseases and Immunology. According to data from OpenAlex, David M. Margolis has authored 304 papers receiving a total of 16.0k indexed citations (citations by other indexed papers that have themselves been cited), including 217 papers in Virology, 183 papers in Infectious Diseases and 78 papers in Immunology. Recurrent topics in David M. Margolis's work include HIV Research and Treatment (217 papers), HIV/AIDS drug development and treatment (150 papers) and HIV/AIDS Research and Interventions (120 papers). David M. Margolis is often cited by papers focused on HIV Research and Treatment (217 papers), HIV/AIDS drug development and treatment (150 papers) and HIV/AIDS Research and Interventions (120 papers). David M. Margolis collaborates with scholars based in United States, United Kingdom and Canada. David M. Margolis's co-authors include Nancie M. Archin, Daria J. Hazuda, Ronald J. Bosch, Douglas D. Richman, Joseph J. Eron, John M. Coffin, Shailesh K. Choudhary, Amy S. Espeseth, Guocheng He and Daniel Parker and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

David M. Margolis

291 papers receiving 15.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

2012 878 citations Nancie M. Archin, Abigail Liberty et al. profile →
The Challenge of Finding a Cure for HIV Infection

2009 664 citations David M. Margolis, Daria J. Hazuda et al. profile →
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

2013 404 citations David M. Margolis et al. profile →
Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies

2015 298 citations JoAnn D. Kuruc, Cynthia L. Gay et al. The Journal of Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David M. Margolis United States	67	10.4k	8.1k	4.2k	3.8k	2.8k	304	16.0k
Suzanne M. Crowe Australia	60	7.0k 0.7×	4.8k 0.6×	5.7k 1.4×	2.5k 0.7×	3.4k 1.2×	265	15.0k
Françoise Barré‐Sinoussi France	63	11.9k 1.1×	7.0k 0.9×	7.5k 1.8×	2.4k 0.6×	4.5k 1.6×	216	17.5k
Sharon R. Lewin Australia	67	9.9k 0.9×	8.0k 1.0×	5.8k 1.4×	2.3k 0.6×	6.6k 2.3×	370	19.0k
Jean‐Pierre Routy Canada	60	8.5k 0.8×	6.1k 0.8×	5.8k 1.4×	2.1k 0.6×	2.9k 1.0×	366	14.4k
Brigitte Autran France	65	8.5k 0.8×	5.8k 0.7×	7.2k 1.7×	1.6k 0.4×	4.5k 1.6×	307	15.8k
Tae‐Wook Chun United States	56	11.7k 1.1×	7.4k 0.9×	6.2k 1.5×	1.7k 0.4×	2.7k 1.0×	116	14.4k
Jan M. Orenstein United States	70	10.3k 1.0×	6.6k 0.8×	6.2k 1.5×	3.7k 1.0×	4.8k 1.7×	213	20.7k
Janet D. Siliciano United States	53	10.2k 1.0×	6.9k 0.8×	4.2k 1.0×	5.2k 1.4×	2.0k 0.7×	104	15.9k
Marcus Altfeld United States	74	10.5k 1.0×	4.7k 0.6×	12.3k 2.9×	2.4k 0.6×	3.3k 1.2×	280	18.0k
Hanneke Schuitemaker Netherlands	63	10.6k 1.0×	6.9k 0.8×	5.8k 1.4×	1.9k 0.5×	2.8k 1.0×	273	13.4k

Countries citing papers authored by David M. Margolis

Since Specialization

Citations

This map shows the geographic impact of David M. Margolis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Margolis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Margolis more than expected).

Fields of papers citing papers by David M. Margolis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Margolis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Margolis. The network helps show where David M. Margolis may publish in the future.

Co-authorship network of co-authors of David M. Margolis

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Margolis. A scholar is included among the top collaborators of David M. Margolis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Margolis. David M. Margolis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Archin, Nancie M., et al.. (2024). A novel high-throughput microwell outgrowth assay for HIV-infected cells. Journal of Virology. 98(3). e0179823–e0179823. 2 indexed citations

Lee, Sook-Kyung, Yinyan Xu, Joanna Warren, et al.. (2024). Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy, Indicating a Lack of Ongoing Viral Replication. Open Forum Infectious Diseases. 11(5). ofae212–ofae212.

Tyers, Lynn, Brian Richardson, Deelan Doolabh, et al.. (2024). The persistent pool of HIV-1-infected cells is formed episodically during untreated infection. Journal of Virology. 99(2). e0097924–e0097924.

Joseph, Sarah, Melissa-Rose Abrahams, Lynn Tyers, et al.. (2024). The timing of HIV-1 infection of cells that persist on therapy is not strongly influenced by replication competency or cellular tropism of the provirus. PLoS Pathogens. 20(2). e1011974–e1011974. 4 indexed citations

Falcinelli, Shane D., Alicia D. Volkheimer, Lesia Semenova, et al.. (2023). Impact of Cannabis Use on Immune Cell Populations and the Viral Reservoir in People With HIV on Suppressive Antiretroviral Therapy. The Journal of Infectious Diseases. 228(11). 1600–1609. 6 indexed citations

Matthews, Andrew, Alexander E. Perl, Selina M. Luger, et al.. (2022). Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Advances. 6(13). 3997–4005. 53 indexed citations

Jefferys, Stuart R., Sara R. Selitsky, Anne‐Marie W. Turner, et al.. (2021). Epigenomic characterization of latent HIV infection identifies latency regulating transcription factors. PLoS Pathogens. 17(2). e1009346–e1009346. 33 indexed citations

Riou, Catherine, Sarah Joseph, Nancie M. Archin, et al.. (2021). Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. Clinical Infectious Diseases. 73(8). 1528–1531. 8 indexed citations

Dashti, Amir, Maud Mavigner, Nils Schoof, et al.. (2020). SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. Journal of Virology. 94(21). 26 indexed citations

10.

Gaebler, Christian, Shane D. Falcinelli, Elina Stoffel, et al.. (2020). Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. Journal of Virology. 95(6). 40 indexed citations

11.

Abrahams, Melissa-Rose, Sarah Joseph, Nigel Garrett, et al.. (2019). The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Science Translational Medicine. 11(513). 132 indexed citations

12.

Meyers, Kathrine, Kristina Rodriguez, Yumeng Wu, et al.. (2017). Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants. AIDS and Behavior. 22(4). 1209–1216. 26 indexed citations

13.

Broglie, Larisa, Lauren Pommert, Sridhar Rao, et al.. (2017). Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Advances. 1(19). 1533–1536. 93 indexed citations

14.

Spreen, William, Susan L. Ford, Shuguang Chen, et al.. (2014). GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(5). 481–486. 117 indexed citations

15.

Archin, Nancie M., Naveen K. Vaidya, JoAnn D. Kuruc, et al.. (2012). Immediate antiviral therapy appears to restrict resting CD4 ⁺ cell HIV-1 infection without accelerating the decay of latent infection. Proceedings of the National Academy of Sciences. 109(24). 9523–9528. 169 indexed citations

16.

Archin, Nancie M., Anna C. Belkina, Gerald V. Denis, et al.. (2012). BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. Journal of Leukocyte Biology. 92(6). 1147–1154. 210 indexed citations

17.

Robertson, K. R., Zhaohui Su, David M. Margolis, et al.. (2010). Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 74(16). 1260–1266. 167 indexed citations

18.

Keedy, Kara S., Nancie M. Archin, Adam Gates, et al.. (2009). A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression. Journal of Virology. 83(10). 4749–4756. 163 indexed citations

19.

DeSmet, Kristina, David Paz, Jesse J. Corry, et al.. (2006). Clinical and Experimental Applications of NIR-LED Photobiomodulation. Photomedicine and Laser Surgery. 24(2). 121–128. 288 indexed citations

20.

Whelan, Harry T., et al.. (2002). NASA Light-Emitting Diodes for the Prevention of Oral Mucositis in Pediatric Bone Marrow Transplant Patients. Journal of Clinical Laser Medicine & Surgery. 20(6). 319–324. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact